{"doi":"10.1007/s00404-018-4660-5","title":"Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer","abstract":null,"journal":"Archives of Gynecology and Obstetrics","year":2018,"id":588658,"datarank":0.7163175418553831,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.3566332509356275,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.3566332509356275,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":9,"citers_with_citation_signal":9,"citers_with_endowment":9,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1505998,"name":"Ewelina Żytko","orcid":null,"position":1,"is_corresponding":false},{"id":1505999,"name":"Justyna Danielska","orcid":null,"position":2,"is_corresponding":false},{"id":1506000,"name":"Bożena Szymańska","orcid":null,"position":3,"is_corresponding":false},{"id":1506001,"name":"Monika Dzieniecka","orcid":null,"position":4,"is_corresponding":false},{"id":1506002,"name":"Marek Nowak","orcid":null,"position":5,"is_corresponding":false},{"id":1506003,"name":"Jakub Malinowski","orcid":null,"position":6,"is_corresponding":false},{"id":1506004,"name":"Dariusz Owczarek","orcid":null,"position":7,"is_corresponding":false},{"id":1506005,"name":"Jacek R. Wilczyński","orcid":null,"position":8,"is_corresponding":false},{"id":1505997,"name":"Miłosz Wilczyński","orcid":"0000-0002-5720-427X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer","abstract":"<h4>Purpose</h4>We aimed to compare expression levels of miRNA-21, -103, -129, -150 in primary tumour tissues and its omental metastases from patients operated for advanced ovarian serous cancer. Expression levels of selected miRNAs were correlated with clinicopathological features, including chemosensitivity and survival.<h4>Methods</h4>We performed total RNA extraction from archival formalin-fixed paraffin-embedded tissue samples of primary serous ovarian cancer and omental metastases. The study included 48 patients with advanced ovarian cancer. The reference group consisted of 48 normal ovarian tissue samples. We performed cDNA synthesis, real time polymerase chain reaction and assessed relative expression of selected miRNAs.<h4>Results</h4>Samples derived from serous ovarian cancer were characterized by higher expression levels of miRNA-150 in comparison to omental metastases (p = 0.045). Furthermore, we observed that shorter progression free-survival was associated with lower levels of miRNA-150 in metastatic tissues. We did not find similar relationships for other miRNAs.<h4>Conclusions</h4>MiRNA-150 may potentially serve as a prognostic factor in advanced ovarian cancer. However, further studies are required to clearly confirm such hypothesis.","is_dataset_classified":null,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"29335784","pmcid":null,"openalex_id":"https://openalex.org/W2783565152","authors":[],"funders":[{"funder_name":"Polish Mother’ss Memorial Hospital Research Institute","grant_id":"2014/VII/25-GW","title":null}],"total_grants":1,"fwci":0.4738,"citation_percentile":0.57448993,"influential_citations":0,"citation_trend":[{"year":2019,"count":3},{"year":2020,"count":2},{"year":2021,"count":1},{"year":2022,"count":2},{"year":2023,"count":1},{"year":2024,"count":1}],"oa_status":"closed","license":"http://www.springer.com/tdm","oa_locations":[{"url":"http://link.springer.com/article/10.1007/s00404-018-4660-5/fulltext.html","host_type":"publisher"},{"url":"http://link.springer.com/content/pdf/10.1007/s00404-018-4660-5.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1007/s00404-018-4660-5","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/29335784","host_type":"repository"}],"fields_of_study":["MicroRNA in disease regulation","Circular RNAs in diseases","Ovarian cancer diagnosis and treatment","Aged","Biomarkers, Tumor","Carcinoma, Ovarian Epithelial","Case-Control Studies","Cystadenocarcinoma, Serous","Female","Gene Expression Regulation, Neoplastic","Humans","MicroRNAs","Middle Aged","Neoplasm Staging","Ovarian Neoplasms","Prognosis","Real-Time Polymerase Chain Reaction","Survival Rate"],"mesh_terms":["Carcinoma, Ovarian Epithelial","Aged","Female","Humans","Middle Aged","Neoplasm Staging","Ovarian Neoplasms","Prognosis","Biomarkers, Tumor","Gene Expression Regulation, Neoplastic","Survival Rate","Case-Control Studies","Cystadenocarcinoma, Serous","MicroRNAs","Real-Time Polymerase Chain Reaction"],"keywords":["Medicine","Serous ovarian cancer","Ovarian cancer","Serous fluid","microRNA","Gynecology","Clinical significance","Human genetics","Oncology","Cancer","Internal medicine","Gene","Genetics","Survival","miRNA","Prognostic factor"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-22T17:17:31.858208Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}